Mode
Text Size
Log in / Sign up

Preclinical analysis of gnomAD and ClinVar databases on ADPLD variant frequencies

Preclinical analysis of gnomAD and ClinVar databases on ADPLD variant frequencies
Photo by Abdul Hakim / Unsplash
Key Takeaway
Consider that predicted ADPLD variant frequencies from genetic databases may not reflect actual disease prevalence.

This is a preclinical analysis of genetic databases, not a clinical trial or observational study. The scope was to analyze gnomAD and ClinVar databases for predicted pathogenic variants in ADPLD genes, which are associated with autosomal dominant polycystic liver disease and kidney cysts. The authors synthesized population frequencies of these predicted variants.

Using a gnomAD v.2.1.1 strategy, the frequency of predicted pathogenic variants was one in 95 people. Using ClinVar assessments of gnomAD v.4.1 variants, the frequency was one in 151 people. Frequencies were higher in specific populations: one in 100 in the admixed American population, one in 107 in the Finnish population, and one in 130 in the African/African American population, all with p <0.0001 compared with Europeans. The frequency in the European population was one in 197.

The authors note that these are frequencies of predicted pathogenic variants and may not reflect actual disease prevalence due to incomplete penetrance and variable expressivity. Limitations were not reported. Practice relevance was not reported. The findings should be interpreted with caution, as this is a preclinical genetic database analysis.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Autosomal dominant polycystic liver disease (ADPLD) commonly results from a pathogenic variant in one of 6 genes (GANAB, ALG8, LRP5, PRKCSH, SEC61B, SEC63). Pathogenic variants in these genes are also associated with kidney cysts, which rarely cause kidney failure, but the genes are included in cystic kidney panels. This study determined the population frequency of predicted pathogenic variants in the ADPLD genes in the general population. Variants for each gene were downloaded from gnomAD and annotated with ANNOVAR. The population frequencies were calculated from the number of people with "predicted pathogenic" variants in gnomAD v.2.1.1:loss-of-function structural and copy number; null; and rare, computationally-damaging missense changes that affected a conserved residue. Frequencies were also estimated from the number of gnomADv.4.1 variants assessed as Pathogenic or Likely pathogenic in ClinVar. Predicted pathogenic variants affected one in 95 people using our strategy and gnomAD v.2.1.1, and one in 151 with ClinVar assessments of gnomAD v.4.1 variants. LRP5 and ALG8 which are associated with a milder clinical phenotype, were the commonest affected genes with both strategies. Predicted pathogenic variants in ADPLD appear more frequent in admixed American (one in 100), Finnish (one in 107) and African/African American (one in 130) people (p all <0.0001 compared with Europeans (one in 197).Predicted pathogenic variants for ADPLD may be even more common because of additional unidentified causative genes. However not all ADPLD variants result in liver cysts, nor indeed cystic kidneys, because of incomplete penetrance and variable expressivity.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.